Want to join the conversation?
$GILD 2Q15 Call: HIV: revenues grew 8% YoverY to $2.7Bil. US revenues grew 21% sequentially to $1.8Bil, driven mostly by April 1st price increase and favorable stock wholesaler inventory levels, and increased demand. Underlying prescription demand remained strong for Stribild and Complera, driving YoverY revenue growth of 58% and 35%, respectively.
$TWTR mentions Snap as one of its fiercest rivals in its 10K filing. Great head start for Snap ahead of IPO!